
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc. is positioned for significant growth due to its innovative TRACER platform, which supports collaborations advancing to clinical trials in the 2030s and is expected to generate revenue. The company’s gene therapies, particularly those utilizing its anti-tau antibody (VY-TAU01) and other silencing technologies, have demonstrated substantial efficacy in preclinical studies, including a remarkable reduction of tau mRNA by up to 73% and protein by over 50% in non-human primates. Additionally, the development of the NeuroShuttle delivery mechanism shows promise in providing prolonged central nervous system exposure, indicating potential safety and efficacy advantages over current treatment methods, reinforcing a favorable outlook for the company's future.
Bears say
Voyager Therapeutics Inc. is facing significant challenges as it navigates the complex landscape of gene therapy development, particularly in its pursuit of effective treatments for severe neurological diseases. The company has experienced setbacks in its clinical trials, leading to concerns about the viability and marketability of its therapeutic candidates, which may adversely impact future revenues. Additionally, Voyager Therapeutics's financial position appears weakened by rising operational costs and diminishing cash reserves, raising doubts about its ability to sustain long-term research and development efforts.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares